Abstract: The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of proADM or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication.

Abstract: The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of pro-adrenomedullin (proADM) or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication.

Abstract: The invention relates to a method of therapy guidance, stratification and/or monitoring of fluid therapy based on proadrenomedullin (proADM) levels. The invention therefore relates to a method for therapy guidance, stratification and/or monitoring of a fluid therapy, comprising providing a sample of said patient, determining a level of pro adrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof indicates the prescription of fluid therapy to be administered to the patient. The invention further relates to methods for guiding fluid therapy volume and to methods of treating disease using fluid therapy based on the proADM stratification of patients based on the methods described herein.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: A sample and related kit and method of treatment including bodily fluid from a patient and proadrenomedullin (proADM) or fragment(s) thereof wherein said proADM) or fragment(s) thereof have been labeled with a luminescence molecule. The patient is an ICU patient, has been diagnosed as being critically ill, and wherein ICU medical treatment has been initiated. The critically ill patient is a patient diagnosed with an infectious disease, and/or is a posttraumatic or postsurgical patient. The level of proADM or fragment(s) thereof in said sample is below 2.25 nmol/l.

Abstract: The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.

Abstract: A method for sample preparation for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for sample preparation for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response. The method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required.

Abstract: A method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, a kit for carrying out the method of the present invention.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The invention pertains to a method for the prognosis and/or risk assessment and/or diagnosis of a major adverse cardio- or cerebrovascular event (MACCE) in a patient who underwent gastrointestinal surgery, the method comprising the steps of: i) providing a sample of a bodily fluid from said patient, ii) determining in said sample the level of a biomarker selected from the group consisting of copeptin, troponin and brain natriuretic peptide (BNP), iii) determining at least one additional parameter of said patient, iv) combining the biomarker level determined in step ii) and the additional parameter determined in step iii) into a combined assessment, and v) correlating the combined assessment to said at least one of prognosis, risk assessment and diagnosis of a MACCE in said patient. The invention further pertains to a kit for carrying out the method, a computer and a computer program product comprising computer-executable code being configured to carry out steps iv) and/or v) of the method of the invention.

Abstract: The invention relates to a method for the diagnosis, prognosis, risk assessment and/or risk stratification of an adverse event in the health of a postsurgical patient, comprising providing at least one sample of a patient, who has undergone, is undergoing or will undergo surgery, wherein the at least one sample has been isolated from the patient presurgically, perioperative or postsurgically, determining a level of at least one biomarker selected from the group consisting of proADM, PCT and pro ET-1 or fragment(s) thereof in said at least one sample, wherein said level of the at least one biomarker or fragment(s) thereof correlates with the likelihood of said adverse event. In some embodiments the method is used for predicting or diagnosing an elevated or decreased likelihood of a postsurgical infection or blood infection.

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

Abstract: The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of pro ADM or fragment(s) thereof in said sample, wherein said level of pro ADM or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication

Abstract: The invention relates to a method for therapy guidance, stratification and/or control in a patient with symptoms of an infectious disease, comprising a prognosis of disease progression, the method comprising: providing a sample from said patient, and determining a level of proADM or fragment(s) thereof in said sample, wherein a low risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is not at risk of a disease progression to a condition that requires hospitalization, wherein said low risk level is preferably equal or below 1.2 nmol/l±20%, and/or wherein a high risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is at risk of a disease progression to a condition that requires hospitalization, wherein said high risk level is preferably above 1.2 nmol/l±20%. The invention further relates to a test kit for carrying out the method.

Abstract: The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.

Abstract: The invention relates to a method for antibiotic therapy guidance, stratification and/or control in a patient suspected of having an infection. In particular, the method comprises providing a sample form said patient, determining a level of proADM or fragment(s) thereof in said sample, and wherein the level of proADM or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. In a preferred embodiment of the invention, the method comprises additionally determining in a sample from said patient a level of PCT or fragment(s) thereof. Furthermore, the invention also relates to a kit for carrying out the method of the present invention.

Abstract: A method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response and suspected of having an infection. Also, a method for antibiotic therapy guidance, stratification and/or control in a patient with one or more comorbidities comprising an impaired innate immune response, wherein the comorbidity is preferably selected from the group comprising metabolic disorder (obesity), diabetes, hypertension, renal disease, thrombosis, malignancy or cancer, and suspected of having an infection. In particular, the method comprises providing a sample from said patient and determining a level of PCT or fragment(s) thereof in said sample, wherein the level of PCT or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. Furthermore, a kit for carrying out the method of the present invention.

Abstract: A method for therapy monitoring, comprising: the prognosis, risk assessment and/or risk stratification of a subsequent adverse event in the health of a patient; providing a sample of said patient, wherein the patient was diagnosed as critically ill and medical treatment initiated, wherein the sample is isolated from the patient after diagnosis and treatment initiation; determining a level of proADM or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the likelihood of a subsequent adverse event in the health of said patient. In a preferred embodiment the invention relates to a method comprising additionally determining a level of procalcitonin (PCT) or fragment(s) thereof in a sample isolated from the patient. Optionally, further determining a level of PCT or fragment(s) thereof in samples isolated from the patient and using the PCT levels also in the prognosis, risk assessment and/or risk stratification.